Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

EMA accepts Pfizer’s bosulif Type II Variation application for Ph+ CML

pharmaceyfical-technologySeptember 01, 2017

Tag: EMA , Ph+ CML , Pfizer’s

PharmaSources Customer Service